NCT01438359

A Drug-Drug Interaction Study of Furosemide and PA21

A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Furosemide in Healthy Male and Female Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 42 (estimated)
• Sponsor: Vifor Pharma · Industry
• Sex: All
• Age: 20 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine if Furosemide is affected by PA21.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	PA21 and Furosemide with food	The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Furosemide will be 40 mg/day
DRUG	No PA21; Furosemide with food	The maximum dosage of Furosemide will be 40 mg/day
DRUG	PA21 with food and Furosemide 2hrs later	The maximum dose of PA21 will be 15 g/day. The maximum dose of Furosemide will be 40 mg/day

Timeline

• Start date: 2011-07-01
• Primary completion: 2011-09-01
• Completion: 2011-09-01
• First posted: 2011-09-22
• Last updated: 2011-09-30

Locations

1 site across 1 country: United States